Understanding how cancer cells resist immune attacks
CTL-killing capacity and cancer stiffness in cancer immunity and therapy
This study is looking at how the stiffness of cancer cells affects how well they can be attacked by immune cells, which could help us understand why some tumors are harder to treat and lead to better ways to boost cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11015764 on NIH RePORTER |
What this research studies
This research investigates the relationship between the stiffness of cancer cells and their ability to be killed by immune cells known as CD8+ T cells. By examining how tumor metabolism and physical properties affect the immune response, the study aims to uncover why some tumors are more resistant to treatment. The researchers will use advanced imaging techniques to measure the elasticity of tumor cells and analyze how these characteristics influence their susceptibility to immune attacks. This could lead to new strategies for enhancing the effectiveness of cancer immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer who are undergoing or considering immunotherapy.
Not a fit: Patients with non-cancerous conditions or those whose tumors are not responsive to immune therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could improve cancer treatment by identifying ways to make tumors more vulnerable to immune attacks.
How similar studies have performed: Other research has shown promising results in understanding tumor-immune interactions, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zou, Weiping — University of Michigan at Ann Arbor
- Study coordinator: Zou, Weiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.